Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ABVC BioPharma, Inc. (ABVC : NSDQ)
 
 • Company Description   
ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, ophthalmology and oncology/hematology indications. ABVC BioPharma Inc. is based in SILICON VALLEY, CA.

Number of Employees: 19

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.35 Daily Weekly Monthly
20 Day Moving Average: 634,413 shares
Shares Outstanding: 16.98 (millions)
Market Capitalization: $56.89 (millions)
Beta: 0.37
52 Week High: $5.48
52 Week Low: $0.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 81.08% 74.30%
12 Week 291.81% 229.57%
Year To Date 467.80% 431.74%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
44370 Old Warm Springs Blvd
-
Fremont,CA 94538
USA
ph: 510-668-0881
fax: -
None http://www.abvcpharma.com
 
 • General Corporate Information   
Officers
Uttam Patil - Chief Executive Officer
Eugene Jiang - Chairman of the Board of Directors
Uttam Patil - Interim Chief Financial Officer
Yen-Hsin Chou - Director
Che-Wei Hsu - Director

Peer Information
ABVC BioPharma, Inc. (CORR.)
ABVC BioPharma, Inc. (RSPI)
ABVC BioPharma, Inc. (CGXP)
ABVC BioPharma, Inc. (BGEN)
ABVC BioPharma, Inc. (GTBP)
ABVC BioPharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00091F304
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 16.98
Most Recent Split Date: 7.00 (0.10:1)
Beta: 0.37
Market Capitalization: $56.89 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.64
Price/Cash Flow: -
Price / Sales: 111.77
EPS Growth
vs. Year Ago Period: 85.00%
vs. Previous Quarter: -250.00%
Sales Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -99.49%
ROE
06/30/25 - -
03/31/25 - -29.62
12/31/24 - -81.67
ROA
06/30/25 - -
03/31/25 - -14.08
12/31/24 - -38.39
Current Ratio
06/30/25 - -
03/31/25 - 0.22
12/31/24 - 0.33
Quick Ratio
06/30/25 - -
03/31/25 - 0.22
12/31/24 - 0.33
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -963.46
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -963.46
Pre-Tax Margin
06/30/25 - -
03/31/25 - -666.53
12/31/24 - -1,052.94
Book Value
06/30/25 - -
03/31/25 - 0.50
12/31/24 - 0.06
Inventory Turnover
06/30/25 - -
03/31/25 - 0.17
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©